tiprankstipranks
Trending News
More News >
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
US Market

Nabriva Therapeutics (NBRVF) Ratios

Compare
1,017 Followers

Nabriva Therapeutics Ratios

NBRVF's free cash flow for Q2 2023 was $-2.53. For the 2023 fiscal year, NBRVF's free cash flow was decreased by $ and operating cash flow was $-4.67. See a summary of the company’s cash flow.
Ratios
TTM
Dec 22Dec 21Dec 20Dec 19
Liquidity Ratios
Current Ratio
1.13 3.59 3.09 5.48-
Quick Ratio
0.78 2.94 2.77 5.44-
Cash Ratio
0.45 2.13 2.23 5.17-
Solvency Ratio
-2.00 -1.77 -2.71 -1.55-
Operating Cash Flow Ratio
-1.33 -2.67 -3.85 -4.32-
Short-Term Operating Cash Flow Coverage
-7.60 -15.82 -34.95 0.00-
Net Current Asset Value
$ 38.33M$ 52.71M$ 31.92M$ 38.33M-
Leverage Ratios
Debt-to-Assets Ratio
0.16 0.10 0.13 0.37-
Debt-to-Equity Ratio
1.59 0.15 0.23 0.84-
Debt-to-Capital Ratio
0.61 0.13 0.19 0.46-
Long-Term Debt-to-Capital Ratio
0.11 0.07 0.15 0.46-
Financial Leverage Ratio
9.65 1.52 1.76 2.28-
Debt Service Coverage Ratio
-10.17 -10.27 -17.21 -21.63-
Interest Coverage Ratio
-79.50 -53.86 -38.11 -21.81-
Debt to Market Cap
2.05 4.87 15.83 122.37-
Interest Debt Per Share
2.21 5.15 18.42 128.53-
Net Debt to EBITDA
0.65 0.84 0.52 0.65-
Profitability Margins
Gross Profit Margin
19.87%51.69%73.25%99.10%-
EBIT Margin
-153.97%-176.58%-2363.69%-1025.93%-
EBITDA Margin
-153.36%-174.24%-2264.42%-1015.99%-
Operating Profit Margin
-155.57%-178.31%-2308.87%-1025.93%-
Pretax Profit Margin
-155.93%-179.89%-2421.26%-1066.89%-
Net Profit Margin
-160.33%-181.69%-2426.12%-1068.20%-
Continuous Operations Profit Margin
-160.33%-181.69%-2426.12%-1068.20%-
Net Income Per EBT
102.82%101.00%100.20%100.12%-
EBT Per EBIT
100.23%100.89%104.87%103.99%-
Return on Assets (ROA)
-87.94%-61.12%-118.91%-87.94%-
Return on Equity (ROE)
-200.52%-92.69%-209.70%-200.52%-
Return on Capital Employed (ROCE)
-102.60%-82.86%-165.68%-102.60%-
Return on Invested Capital (ROIC)
-102.73%-78.63%-157.94%-102.73%-
Return on Tangible Assets
-88.03%-61.14%-119.07%-88.03%-
Earnings Yield
-29353.40%-3001.92%-14235.20%-29353.40%-
Efficiency Ratios
Receivables Turnover
5.29 2.13 0.73 2.82-
Payables Turnover
5.26 3.01 0.27 0.01-
Inventory Turnover
2.95 0.91 0.13 0.10-
Fixed Asset Turnover
127.39 116.81 3.73 3.13-
Asset Turnover
1.12 0.34 0.05 0.08-
Working Capital Turnover Ratio
1.16 0.56 0.05 0.09-
Cash Conversion Cycle
-20.68K 452.42 1.90K -20.68K-
Days of Sales Outstanding
129.27 171.01 498.18 129.27-
Days of Inventory Outstanding
3.56K 402.78 2.77K 3.56K-
Days of Payables Outstanding
24.37K 121.37 1.38K 24.37K-
Operating Cycle
3.69K 573.79 3.27K 3.69K-
Cash Flow Ratios
Operating Cash Flow Per Share
-13.69 -34.35 -138.83 -242.23-
Free Cash Flow Per Share
-13.77 -34.36 -139.05 -242.43-
CapEx Per Share
0.08 0.01 0.22 0.21-
Free Cash Flow to Operating Cash Flow
1.01 1.00 1.00 1.00-
Dividend Paid and CapEx Coverage Ratio
-173.99 -2.38K -631.25 -1.18K-
Capital Expenditure Coverage Ratio
-173.99 -2.38K -631.25 -1.18K-
Operating Cash Flow Coverage Ratio
-7.03 -7.42 -9.23 -2.08-
Operating Cash Flow to Sales Ratio
-1.03 -2.19 -24.91 -9.28-
Free Cash Flow Yield
-25519.13%-3616.99%-14636.75%-25519.13%-
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-0.04 -0.03 >-0.01 >-0.01-
Price-to-Sales (P/S) Ratio
0.07 0.06 0.17 0.04-
Price-to-Book (P/B) Ratio
0.77 0.03 0.01 <0.01-
Price-to-Free Cash Flow (P/FCF) Ratio
-0.07 -0.03 >-0.01 >-0.01-
Price-to-Operating Cash Flow Ratio
-0.07 -0.03 >-0.01 >-0.01-
Price-to-Earnings Growth (PEG) Ratio
<0.01 <0.01 <0.01 <0.01-
Price-to-Fair Value
0.77 0.03 0.01 <0.01-
Enterprise Value Multiple
0.08 0.80 0.51 0.65-
Enterprise Value
-51.24M -37.98M -33.14M -51.24M-
EV to EBITDA
0.65 0.80 0.51 0.65-
EV to Sales
-6.61 -1.40 -11.57 -6.61-
EV to Free Cash Flow
0.71 0.64 0.46 0.71-
EV to Operating Cash Flow
0.71 0.64 0.46 0.71-
Tangible Book Value Per Share
1.23 30.77 64.49 139.06-
Shareholders’ Equity Per Share
1.23 30.77 64.49 139.06-
Tax and Other Ratios
Effective Tax Rate
-0.03 -0.01 >-0.01 >-0.01-
Revenue Per Share
13.30 15.70 5.57 26.11-
Net Income Per Share
-21.32 -28.52 -135.23 -278.86-
Tax Burden
1.00 1.01 1.00 1.00-
Interest Burden
1.04 1.02 1.02 1.04-
Research & Development to Revenue
3.41 0.46 5.27 3.41-
SG&A to Revenue
0.00 0.00 0.00 0.00-
Stock-Based Compensation to Revenue
1.26 0.12 1.82 1.26-
Income Quality
0.87 1.20 1.03 0.87-
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis